Nexell gets license to Diaclone antibodies

NEXL converted its global licensing agreement with Diaclone (Besancon, France) to an exclusive license to six MAbs for use in ex vivo cell therapy (see BioCentury, Jan. 31). NEXL gets rights to produ...